Neuren Pharmaceuticals [ASX: NEU] has concluded patient recruitment and dosing for its Phase III clinical trial of Glypromate, a therapeutic designed to reduce brain impairment after major heart surgery.

The recruitment of 320 patients has been concluded ahead of schedule, and Neuren is expecting to release provisional efficacy results before the end of the year.

Up to a third of patients suffer cognitive impairment three months after major heart surgery, and there is currently no approved treatment to prevent it.